Oncology compounds are prevalent in pharmaceutical pipelines but many are poorly water soluble in gastrointestinal fluids, often manifesting as drug-drug or food-drug interactions that limit oral bioavailability. An amorphous solid dispersion (ASD) tablet of the weak base drug, acalabrutinib, that removed the pH effect observed with commercially marketed Calquence® at the human dose in dogs and gave higher exposure with a 60% smaller dosage form.

Watch this on-demand presentation to:

  • Understand how ASD drug products can enhance oral bioavailability and overcome pH effects of poorly-soluble weak base drugs.
  • Learn how knowledge of key drug, polymer, and gastrointestinal properties can be combined with in vitro and in silico tools to develop ASD drug products without the need for reformulation or multiple studies.
  • Describe key considerations driving effective selection of ASD formulations

Content Type: Presentation (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center